Diabetes &
Primary Care

Issue:

Share this article

+ Add to reading list - Remove from my list

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Stephen Bain

An unexpected safety signal emerged from the SUSTAIN 6 cardiovascular outcomes trial of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide, whereby increased rates of diabetic retinopathy were observed in trial participants randomised to semaglutide. This finding has, justifiably, led to a great deal of investigation and caution. This At a Glance factsheet outlines the evidence regarding diabetic retinopathy in users of the GLP-1 RA class as a whole, and provides recommendations on safe use.

Save, Share, Print Article

Share this article

+ Add to reading list – Remove from reading list

↓ Download pdf

Readers are directed to the PDF version of this article.

At a glance factsheet, Microvascular complications, Newer therapies, Retinopathy

Diabetes &
Primary Care

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Interactive case study: Non-diabetic hyperglycaemia – Prediabetes

Diabetes Distilled: Smoking cessation cuts excess mortality rates after as little as 3 years

Impact of Freestyle Libre 2 on diabetes distress and glycaemic control in people on twice-daily pre-mixed insulin

Updated guidance from the PCDS and ABCD: Managing the national GLP-1 RA shortage

Diabetes Distilled: Fib-4 – A diagnostic and prognostic marker for liver and cardiovascular events and mortality

At a glance factsheet: Tirzepatide for management of type 2 diabetes

Editorial: Lipid management, tirzepatide and hybrid closed-loop: What does new NICE guidance recommend?